Block listing update

RNS Number : 0387J

Futura Medical PLC

30 November 2018

 

Block Listing Update

30 November 2018

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

The table below provides further detail. The figures include the block admission of 1,765,000 Ordinary Shares earlier today, as announced on 26 November 2018.

Name of company:

Futura Medical plc

Name of scheme(s):

Unapproved Share Option Scheme ("USOS") Unapproved Share Incentive Scheme ("USIS") EMI Share Option Scheme ("EMI")

Period of return:

From:

31 May 2018

To:

30 November 2018

Number and class of securities not issued under the scheme(s) at beginning of period

USOS:

2,343,965

USIS:

-

EMI:

2,843,535

Total:

5,187,500

Number and class of securities admitted to the scheme(s) in the period

USOS:

-

USIS:

425,000

EMI:

1,340,000

Total:

1,765,000

Number of securities issued under the scheme(s) during the period

USOS:

-

USIS:

-

EMI:

-

Total:

-

Number of securities lapsed under the scheme(s) during the period

USOS:

350,090

USIS:

-

EMI:

377,410

Total:

727,500

Balance of securities under the scheme(s) not yet issued at the end of the period

USOS:

1,993,875

USIS:

425,000

EMI:

3,806,125

Total:

6,225,000

Number and class of securities originally admitted and the date of admission

USOS:

814,424 25 May 2011,  1,202,280 8 October 2013, 1,466,208 25 May 2017, 400,000 30 May 2018,

USOS Total:

3,882,912

USIS:

425,000 30 November 2018

USIS Total:

425,000

EMI:

1,520,576 25 May 2011, 1,467,720 8 October 2013, 1,893,792 25 May 2017, 790,000 30 May 2018, 1,340,000 30 November 2018

EMI Total:

7,012,088

Total:

11,320,000

Name of contact:

Angela Hildreth, Finance Director/Chief Operating Officer

Telephone number of contact:

[phone]

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

Nominated Adviser and Broker:

N+1 Singer

Aubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

 

END

 

 

BLRWGGQCGUPRURU